Candriam S.C.A. Exact Sciences Corp Transaction History

Candriam S.C.A.

$16.8 Billion
Q2 2025

A detailed history of Candriam S.C.A. transactions in Exact Sciences Corp stock. As of the latest transaction made, Candriam S.C.A. holds 345,399 shares of EXAS stock, worth $21.9 Million. This represents 0.11% of its overall portfolio holdings.

Number of Shares

345,399

Previous 356,975 3.24%

Holding current value

$21.9 Million

Previous $15.5 Million 18.77%

% of portfolio

0.11%

Previous 0.1%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 08, 2025	SELL	$40.31 - $58.08 $466,628 - $672,334	-11,576 Reduced 3.24%	345,399 $18.4 Million
Q1 2025 May 14, 2025	SELL	$43.04 - $58.51 $201,771 - $274,294	-4,688 Reduced 1.3%	356,975 $15.5 Million
Q4 2024 Feb 06, 2025	SELL	$49.33 - $71.97 $4.68 Million - $6.83 Million	-94,928 Reduced 20.79%	361,663 $20.3 Million
Q3 2024 Nov 13, 2024	BUY	$42.43 - $70.83 $10.4 Million - $17.3 Million	244,064 Added 114.84%	456,591 $31.1 Million
Q2 2024 Aug 05, 2024	BUY	$41.33 - $74.26 $651,939 - $1.17 Million	15,774 Added 8.02%	212,527 $8.98 Million
Q1 2024 May 03, 2024	SELL	$56.27 - $73.77 $4.61 Million - $6.04 Million	-81,917 Reduced 29.4%	196,753 $13.6 Million
Q4 2023 Feb 14, 2024	BUY	$59.06 - $75.72 $7.77 Million - $9.96 Million	131,582 Added 89.46%	278,670 $20.6 Million
Q3 2023 Nov 13, 2023	BUY	$65.94 - $99.04 $9.04 Million - $13.6 Million	137,169 Added 1382.89%	147,088 $10 Million
Q2 2023 Aug 08, 2023	SELL	$62.68 - $95.05 $455,495 - $690,728	-7,267 Reduced 42.28%	9,919 $931,000
Q1 2023 May 12, 2023	BUY	$47.19 - $70.77 $247,794 - $371,613	5,251 Added 44.0%	17,186 $1.17 Million
Q4 2022 Feb 13, 2023	SELL	$30.35 - $53.15 $3.47 Million - $6.08 Million	-114,324 Reduced 90.55%	11,935 $590,000
Q3 2022 Nov 10, 2022	BUY	$31.97 - $49.37 $3.79 Million - $5.85 Million	118,424 Added 1511.47%	126,259 $4.1 Million
Q2 2022 Aug 03, 2022	SELL	$35.61 - $76.23 $157,503 - $337,165	-4,423 Reduced 36.08%	7,835 $309,000
Q1 2022 May 13, 2022	SELL	$57.56 - $82.54 $12.9 Million - $18.5 Million	-224,575 Reduced 94.82%	12,258 $857,000
Q4 2021 Feb 10, 2022	BUY	$72.5 - $100.68 $433,115 - $601,462	5,974 Added 2.59%	236,833 $18.4 Million
Q3 2021 Nov 09, 2021	SELL	$90.24 - $124.05 $733,921 - $1.01 Million	-8,133 Reduced 3.4%	230,859 $22 Million
Q2 2021 Jul 20, 2021	BUY	$93.66 - $139.27 $5.91 Million - $8.79 Million	63,118 Added 35.89%	238,992 $29.7 Million
Q1 2021 Apr 29, 2021	SELL	$116.57 - $155.01 $233 - $310	-2 Reduced -0.0%	175,874 $22.4 Million
Q4 2020 Jan 22, 2021	SELL	$99.61 - $142.12 $6.64 Million - $9.48 Million	-66,704 Reduced 27.5%	175,876 $23.3 Million
Q3 2020 Oct 19, 2020	BUY	$72.92 - $102.01 $3.99 Million - $5.58 Million	54,652 Added 29.08%	242,580 $24.7 Million
Q2 2020 Jul 23, 2020	BUY	$55.75 - $92.75 $3.99 Million - $6.64 Million	71,571 Added 61.51%	187,928 $16.3 Million
Q1 2020 May 26, 2020	BUY	$37.9 - $104.44 $947 - $2,611	25 Added 0.02%	116,357 $10.5 Million
Q4 2019 Jan 21, 2020	BUY	$77.66 - $99.74 $4.79 Million - $6.15 Million	61,690 Added 112.9%	116,332 $11,000
Q3 2019 Oct 21, 2019	BUY	$90.37 - $122.49 $1.82 Million - $2.47 Million	20,183 Added 58.57%	54,642 $5,000
Q2 2019 Aug 01, 2019	BUY	$89.51 - $118.04 $957,757 - $1.26 Million	10,700 Added 45.04%	34,459 $4.05 Million
Q1 2019 May 02, 2019	BUY	$61.98 - $96.5 $1.18 Million - $1.83 Million	18,994 Added 398.61%	23,759 $2.06 Million
Q4 2018 Feb 14, 2019	BUY	$56.04 - $82.66 $267,030 - $393,874	4,765 New	4,765 $301,000

Others Institutions Holding EXAS

# of Institutions

656

Shares Held

158M

Call Options Held

1.43M

Put Options Held

2.3M

View Full List

About EXACT SCIENCES CORP

Ticker EXAS
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 176,960,000
Market Cap $11.2B
Description
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...

More about EXAS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

News

Stay updated on Candriam S.C.A. with notifications on news.

Account